stable, treated patients with schizophrenia [9]. A systematic review of the therapeutic potential of CBD and higher CBD cannabis preparations for psychosis and schizophrenia describes a promising future with effective and tolerable results thus far [76]. Moreover, published on the ClinicalTrials.gov database, there are currently two active, but not yet recruiting, clinical trials that will assess CBD in acute schizophrenia (NCT02088060), as well as in early psychosis (NCT02504151). There are also two completed trials that have assessed CBD in acute psychosis (NCT00628290) and in schizophrenia or schizophreniform disorder (NCT00309413), but have no published results. Randomized mulit-site clinical trials are needed to substantiate the external validity of these trials.
